$SRNE
Sorrento Therapeutics Inc

2022 Q1 Form 10-Q Financial Statement

#000095017022007887 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $18.39M $14.26M
YoY Change 28.97% 84.63%
Cost Of Revenue $5.758M $3.400M
YoY Change 69.35% 41.67%
Gross Profit $12.63M $10.90M
YoY Change 15.84% 105.66%
Gross Profit Margin 68.68% 76.46%
Selling, General & Admin $44.33M $43.40M
YoY Change 2.14% 65.02%
% of Gross Profit 351.05% 398.17%
Research & Development $63.98M $43.83M
YoY Change 45.96% 107.21%
% of Gross Profit 506.67% 402.14%
Depreciation & Amortization $3.298M $2.920M
YoY Change 12.95% -4.58%
% of Gross Profit 26.12% 26.79%
Operating Expenses $63.98M $43.83M
YoY Change 45.96% 107.21%
Operating Profit -$106.9M -$84.91M
YoY Change 25.89% 96.71%
Interest Expense $3.249M $2.366M
YoY Change 37.32% -65.24%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$38.95M $2.212M
YoY Change -1860.67% -103.21%
Income Tax $1.500M -$200.0K
% Of Pretax Income -9.04%
Net Earnings -$40.82M $2.510M
YoY Change -1726.1% -103.85%
Net Earnings / Revenue -222.0% 17.61%
Basic Earnings Per Share -$0.12 $0.01
Diluted Earnings Per Share -$0.12 $0.01
COMMON SHARES
Basic Shares Outstanding 337.1M 280.6M
Diluted Shares Outstanding 337.1M 297.9M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $270.7M $236.1M
YoY Change 14.64% 978.08%
Cash & Equivalents $111.9M $41.68M
Short-Term Investments $158.8M $194.4M
Other Short-Term Assets $8.140M $3.848M
YoY Change 111.54% -73.82%
Inventory $14.09M $1.800M
Prepaid Expenses $13.56M $7.656M
Receivables $24.67M $16.30M
Other Receivables $0.00 $0.00
Total Short-Term Assets $331.1M $265.7M
YoY Change 24.62% 435.34%
LONG-TERM ASSETS
Property, Plant & Equipment $41.71M $34.68M
YoY Change 20.25% 21.82%
Goodwill $79.50M $43.60M
YoY Change 82.34% 13.84%
Intangibles $258.7M $72.64M
YoY Change 256.1%
Long-Term Investments $50.67M $156.0M
YoY Change -67.52% 532.19%
Other Assets $9.059M $2.000M
YoY Change 352.95% -58.11%
Total Long-Term Assets $524.5M $347.9M
YoY Change 50.77% -28.55%
TOTAL ASSETS
Total Short-Term Assets $331.1M $265.7M
Total Long-Term Assets $524.5M $347.9M
Total Assets $855.6M $613.6M
YoY Change 39.45% 14.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $25.02M $25.10M
YoY Change -0.33% -13.41%
Accrued Expenses $48.15M $47.70M
YoY Change 0.94% 234.95%
Deferred Revenue $673.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $56.94M $21.70M
YoY Change 162.41% 30.84%
Total Short-Term Liabilities $204.2M $96.04M
YoY Change 112.64% 6.54%
LONG-TERM LIABILITIES
Long-Term Debt $96.09M $79.96M
YoY Change 20.17% -56.3%
Other Long-Term Liabilities $1.761M $549.0K
YoY Change 220.77% 0.0%
Total Long-Term Liabilities $97.85M $80.51M
YoY Change 21.54% -56.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $204.2M $96.04M
Total Long-Term Liabilities $97.85M $80.51M
Total Liabilities $629.4M $382.7M
YoY Change 64.46% -21.14%
SHAREHOLDERS EQUITY
Retained Earnings -$1.427B -$955.8M
YoY Change 49.35% 31.83%
Common Stock $1.704B $1.236B
YoY Change 37.81% 41.16%
Preferred Stock
YoY Change
Treasury Stock (at cost) $49.46M $49.46M
YoY Change 0.0% 0.0%
Treasury Stock Shares $7.568M $7.568M
Shareholders Equity $226.5M $231.4M
YoY Change
Total Liabilities & Shareholders Equity $855.6M $613.6M
YoY Change 39.44% 14.36%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$40.82M $2.510M
YoY Change -1726.1% -103.85%
Depreciation, Depletion And Amortization $3.298M $2.920M
YoY Change 12.95% -4.58%
Cash From Operating Activities -$83.36M -$48.06M
YoY Change 73.46% 24.66%
INVESTING ACTIVITIES
Capital Expenditures $2.593M $1.994M
YoY Change 30.04% 9395.24%
Acquisitions $4.527M $12.00K
YoY Change 37625.0%
Other Investing Activities -$11.07M -$10.00K
YoY Change 110610.0%
Cash From Investing Activities -$13.66M -$2.006M
YoY Change 581.16% 9452.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $48.32M $29.22M
YoY Change 65.36% -50.92%
Cash From Financing Activities 173.4M 35.36M
YoY Change 390.34% 43.02%
NET CHANGE
Cash From Operating Activities -83.36M -48.06M
Cash From Investing Activities -13.66M -2.006M
Cash From Financing Activities 173.4M 35.36M
Net Change In Cash 76.35M -14.71M
YoY Change -619.14% 6.19%
FREE CASH FLOW
Cash From Operating Activities -$83.36M -$48.06M
Capital Expenditures $2.593M $1.994M
Free Cash Flow -$85.95M -$50.05M
YoY Change 71.73% 29.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000850261
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-36150
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
SORRENTO THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0344842
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4955 Directors Place
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2022Q1 dei City Area Code
CityAreaCode
858
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
203-4100
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2022Q1 dei Trading Symbol
TradingSymbol
SRNE
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
388946453
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111906000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36665000
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
158751000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
90217000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24674000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18715000
CY2022Q1 us-gaap Inventory Net
InventoryNet
14086000
CY2021Q4 us-gaap Inventory Net
InventoryNet
8106000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
13558000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11804000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
8140000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
7482000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
331115000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
172989000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41705000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41325000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
84894000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
85173000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
258671000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
259705000
CY2022Q1 us-gaap Goodwill
Goodwill
79525000
CY2021Q4 us-gaap Goodwill
Goodwill
79525000
CY2022Q1 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
50667000
CY2021Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
51271000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9059000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4830000
CY2022Q1 us-gaap Assets
Assets
855636000
CY2021Q4 us-gaap Assets
Assets
694818000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
25018000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
27414000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25391000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21503000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48149000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
37975000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
673000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
49464000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
226542000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
78748000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1108000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12451000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11539000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
28068000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
397000
CY2022Q1 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
7537000
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
7537000
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
56942000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
31980000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
204229000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
139453000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
96085000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
110627000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3512000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2426000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
117667000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
118942000
CY2022Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
28200000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
35700000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
83406000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
83431000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
94578000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
124349000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1761000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1761000
CY2022Q1 us-gaap Liabilities
Liabilities
629438000
CY2021Q4 us-gaap Liabilities
Liabilities
616689000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
375168017
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
375168017
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
314573225
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
314573225
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
38000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1703610000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1513758000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-223000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1026000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1427419000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1386604000
CY2022Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
7568182
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
7568182
CY2022Q1 us-gaap Treasury Stock Value
TreasuryStockValue
49464000
CY2022Q1 us-gaap Minority Interest
MinorityInterest
-344000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
-619000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
226198000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
78129000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
855636000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
694818000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
18385000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14255000
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
63977000
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
43833000
CY2022Q1 srne Research And Development In Process And Impairment Of Intangible Assets Finite Lived
ResearchAndDevelopmentInProcessAndImpairmentOfIntangibleAssetsFiniteLived
12272000
CY2021Q1 srne Research And Development In Process And Impairment Of Intangible Assets Finite Lived
ResearchAndDevelopmentInProcessAndImpairmentOfIntangibleAssetsFiniteLived
7512000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44327000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43394000
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1034000
CY2021Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1035000
CY2022Q1 srne Gain Loss On Contingent Consideration
GainLossOnContingentConsideration
-2100000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
125268000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
99160000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-106883000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-84905000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7500000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2200000
CY2022Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
68534000
CY2021Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
94431000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5262000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6111000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
397000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-540000
CY2022Q1 us-gaap Interest Expense
InterestExpense
3249000
CY2021Q1 us-gaap Interest Expense
InterestExpense
2366000
CY2022Q1 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
17000
CY2021Q1 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-78000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-38946000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2631000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1463000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-206000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-131000
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-419000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-40540000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
2418000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
275000
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-92000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-40815000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2510000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
337123000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
280604000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
337123000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
297909000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-40540000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
2418000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1249000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-75000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1249000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-75000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-41789000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
2343000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
275000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-92000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42064000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2435000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
78129000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
164437000
CY2022Q1 srne Acquisitions Consideration Paid In Equity
AcquisitionsConsiderationPaidInEquity
4435000
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
20854000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1249000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-40540000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
226198000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
140731000
CY2021Q1 srne Stock Issued During Period Value Upon Issuance Of Warrants
StockIssuedDuringPeriodValueUponIssuanceOfWarrants
9050000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
42209000
CY2021Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
7500000
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
23660000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-75000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
2418000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
230887000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-40540000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
2418000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3298000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2918000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
987000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
759000
CY2022Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
2906000
CY2021Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
2098000
CY2022Q1 srne Payment Notes Attributed To Accreted Interest Related To Debt Discount
PaymentNotesAttributedToAccretedInterestRelatedToDebtDiscount
6788000
CY2021Q1 srne Payment Notes Attributed To Accreted Interest Related To Debt Discount
PaymentNotesAttributedToAccretedInterestRelatedToDebtDiscount
4548000
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
12271000
CY2021Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
7512000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
20792000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
23660000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5262000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6111000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7500000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2200000
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
68534000
CY2021Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
94431000
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-131000
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-419000
CY2022Q1 srne Gain On Contingent Consideration
GainOnContingentConsideration
2100000
CY2021Q1 srne Gain On Contingent Consideration
GainOnContingentConsideration
0
CY2022Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
1086000
CY2021Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-219000
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
5982000
CY2021Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
803000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5979000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-51000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3949000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4573000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1640000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-929000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2571000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-76000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9122000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
11066000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1709000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
376000
CY2022Q1 srne Deferred Rent And Other Period Increase Decrease
DeferredRentAndOtherPeriodIncreaseDecrease
179000
CY2021Q1 srne Deferred Rent And Other Period Increase Decrease
DeferredRentAndOtherPeriodIncreaseDecrease
476000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83360000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48057000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2593000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1994000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13664000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2006000
CY2022Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
57121000
CY2021Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
11769000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
132000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10597000
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
48316000
CY2021Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
29218000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
173369000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35357000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
76345000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14706000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1104000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-80000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36665000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56464000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111906000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41678000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
116000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
83000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
53000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022Q1 srne Changes To Noncontrolling Interests From Increased Ownership
ChangesToNoncontrollingInterestsFromIncreasedOwnership
0
CY2021Q1 srne Changes To Noncontrolling Interests From Increased Ownership
ChangesToNoncontrollingInterestsFromIncreasedOwnership
23963000
CY2022Q1 srne Noncash Or Part Noncash Acquisition Value Of Equity Assumed
NoncashOrPartNoncashAcquisitionValueOfEquityAssumed
4435000
CY2021Q1 srne Noncash Or Part Noncash Acquisition Value Of Equity Assumed
NoncashOrPartNoncashAcquisitionValueOfEquityAssumed
0
CY2022Q1 srne Other Acquisitions License Agreements And Investments Paid In Equity
OtherAcquisitionsLicenseAgreementsAndInvestmentsPaidInEquity
0
CY2021Q1 srne Other Acquisitions License Agreements And Investments Paid In Equity
OtherAcquisitionsLicenseAgreementsAndInvestmentsPaidInEquity
7500000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
457000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1031000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">To prepare consolidated financial statements in conformity with accounting principles generally accepted in the U.S., management must make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></p>
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7500000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2200000
CY2022Q1 us-gaap Goodwill
Goodwill
79500000
CY2022Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
218400000
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
279210000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
20539000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
258671000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
279210000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19505000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
259705000
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1000000.0
CY2021Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1000000.0
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3106000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4048000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3870000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3845000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3845000
CY2021Q3 srne Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
21527000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40241000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
22515513
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.19
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
990246
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.88
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15499
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.37
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
21509768
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.16
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
803000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
10371000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
14386000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
14410000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13625000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13367000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
13564000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
152626000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3433896
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
9.50
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2022Q1 srne Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
422488
CY2022Q1 srne Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue
10.18
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
231145
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
9.59
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2780263
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
9.39
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2894000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2487000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
632000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P14Y9M18D
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y2M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.128
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.122
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
232349000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
136492000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
95857000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1500000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.037
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.093
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.037
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-40815000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2510000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-40815000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2510000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
337123000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
280604000
CY2021Q1 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
17305000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
337123000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
297909000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23648000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2987000
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
18385000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14255000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
125268000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
99160000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-106883000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-84905000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111906000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41678000

Files In Submission

Name View Source Status
0000950170-22-007887-index-headers.html Edgar Link pending
0000950170-22-007887-index.html Edgar Link pending
0000950170-22-007887.txt Edgar Link pending
0000950170-22-007887-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
srne-20220331.htm Edgar Link pending
srne-20220331.xsd Edgar Link pending
srne-20220331_cal.xml Edgar Link unprocessable
srne-20220331_def.xml Edgar Link unprocessable
srne-20220331_htm.xml Edgar Link completed
srne-20220331_lab.xml Edgar Link unprocessable
srne-20220331_pre.xml Edgar Link unprocessable
srne-ex10_1.htm Edgar Link pending
srne-ex10_2.htm Edgar Link pending
srne-ex31_1.htm Edgar Link pending
srne-ex32_1.htm Edgar Link pending